Yuncheng Technology lands ¥50M Series A to scale AI-driven data platform for China's pharma sector

What's the deal? Yuncheng Technology, a Chinese startup building data and AI tools for the life sciences industry, has closed a ¥50M ($7M) Series A round led by Gobi PartnersDealroom has a profile for this one. Try Dealroom →.

The company has developed a proprietary data platform called Wukong 3.0, which provides end-to-end cloud solutions for pharmaceutical companies across production, clinical trials, and marketing operations.

Why now? China's pharmaceutical sector is under growing pressure to digitise. Yuncheng says it already serves the top 20 global multinational pharma companies as well as major domestic drugmakers — a client base that suggests strong product-market fit ahead of this funding round.

The intersection of AI and life sciences has attracted significant investor interest globally, and Chinese startups operating in pharma enterprise software are riding that wave.

What could go wrong? Enterprise software for pharma is a competitive and heavily regulated space. Yuncheng faces both domestic rivals and global incumbents with deep pockets. Scaling beyond its current client base while maintaining the customisation large pharma companies demand will be a key challenge.

The signal: Gobi Partners, a cross-border investment fund with deep roots in China and Southeast Asia, backing an early-growth vertical SaaS player underscores growing investor appetite for AI tools purpose-built for regulated industries. With Yuncheng already embedded in the workflows of the top 20 global pharma companies, the round positions it to deepen those relationships as China's life sciences sector accelerates its digital overhaul.

Read more: ITjuzi